Actively Recruiting
Evaluating Armored DLL3-SAVVYZ-IL18 CAR T Cells for Treatment of DLL3-Positive Neuroendocrine Cancers Including Small Cell Lung Cancer
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-10-22
16
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety of DLL3-SAVVYZ-IL18 CAR T cells in people with DLL3-positive cancers, including various neuroendocrine tumors such as small cell lung cancer and others that express DLL3. This phase 1 trial aims to find the maximum tolerated dose of this investigational CAR T cell therapy for treating these advanced cancers. Participants receive DLL3-SAVVYZ-IL18 CAR T cells at different dose levels depending on safety results from earlier doses. The study involves a sequential design with three dose levels, including a starting dose and adjusted doses based on observed toxicities. The treatment is given after collecting the participants own T cells and may include patients who have received prior systemic therapies. During the study, participants undergo evaluations including tumor measurements, organ function tests, and performance status assessments. Researchers monitor safety and tolerability for up to one year to determine the best dosing. Participants must meet specific health criteria and will be followed closely throughout the trial period, which runs until August 2029.
CONDITIONS
Brief Title
A Study of Armored CAR T Cells in People With Cancer
Research Team
A
Adam Schoenfeld, MD
R
Ritesh Kotecha, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here